Recombinant human growth hormone (rhGH) is effective in pubertal patients.
Recombinant human growth hormone (rhGH) therapy in a dose of 28-30 i.u./m2/week results in a significant and sustained improvement of height in most pubertal patients with growth retardation secondary to chronic renal insufficiency (CRI), dialysis or after renal transplantation (RTx). Long-term data indicate that rhGH therapy leads to a significant improvement in the final height of growth-retarded pubertal patients after renal transplantation.